Welcome to Galantos Pharma GmbH

Galantos Pharma is a biopharmaceutical company focusing on the research and development of novel drugs for the treatment of neurodegenerative diseases, in particular Alzheimer‘s Disease (AD).

Galantos Pharma GmbH was founded in 2005 in Mainz by Professors Alfred Maelicke (Mainz) and Ulrich Jordis (Vienna) who both have been crucially involved in the development of the natural product galantamine for the treatment of AD.

Galantos is developing Memogain for the treatment of Alzheimer‘s Disease. The goal is to improve efficacy and abolish gastrointestinal side effects. At present, Memogain is in late preclinical development and anticipated to enter clinical trials at the end of 2010. Galantos is aiming to provide proof-of-concept in man with the funds from a current investment round and then licensing to a pharma partner for further clinical development and marketing.

Galantos has started a project to develop new neuroprotective and cognition improving compounds from its novel lead structures. The government (BMBF) co-funded project is focussed on Galantos' experience with allosteric modulators of nicotinic receptors and performed in collaboration with acedemic and CRO experts.

Click here for further information on Memogain

To download a Company Profile of Galantos, please click here.